SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vineet Laboratories - Quaterly Results

12 May 2025 Evaluate
The Sales for the quarter ended March 2025 of Rs. 140.77 million declined by -62.00% from Rs. 370.49 millions.The Net Loss for the quarter ended March 2025 is Rs. -105.25 millions as compared to Net Profit of Rs. 19.23 millions of corresponding quarter ended March 2024Operating profit Margin for the quarter ended March 2025 slipped to -96.64% as compared to 38.26% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 140.77 370.49 -62.00 749.95 1505.91 -50.20 749.95 1505.91 -50.20
Other Income 13.81 4.11 236.01 19.87 4.63 329.16 19.87 4.63 329.16
PBIDT -96.64 38.26 -352.59 -142.96 76.63 -286.56 -142.96 76.63 -286.56
Interest 9.00 17.21 -47.70 39.78 47.81 -16.80 39.78 47.81 -16.80
PBDT -105.64 21.05 -601.85 -182.74 28.82 -734.07 -182.74 28.82 -734.07
Depreciation 6.57 6.72 -2.23 25.02 25.19 -0.67 25.02 25.19 -0.67
PBT -112.21 14.33 -883.04 -207.76 3.63 -5823.42 -207.76 3.63 -5823.42
TAX -6.96 -4.90 42.04 -5.85 -6.64 -11.90 -5.85 -6.64 -11.90
Deferred Tax -6.96 -6.13 13.54 -5.85 -5.99 -2.34 -5.85 -5.99 -2.34
PAT -105.25 19.23 -647.32 -201.91 10.27 -2066.02 -201.91 10.27 -2066.02
Equity 92.19 92.19 0.00 92.19 92.19 0.00 92.19 92.19 0.00
PBIDTM(%) -68.65 10.33 -764.78 -19.06 5.09 -474.61 -19.06 5.09 -474.61

Vineet Laboratories Share Price

39.50 -0.19 (-0.48%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×